{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:47:05Z","timestamp":1793119625262,"version":"4.5.0"},"reference-count":32,"publisher":"European Respiratory Society (ERS)","issue":"4","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015277","name":"Roche Products","doi-asserted-by":"publisher","award":["Unrestricted research grant"],"award-info":[{"award-number":["Unrestricted research grant"]}],"id":[{"id":"10.13039\/100015277","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2025,10,3]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Chronic lung allograft dysfunction (CLAD) is a major obstacle to improving outcomes after lung transplantation. Bronchiolitis obliterans syndrome (BOS), characterised by progressive decline in forced expiratory volume in 1\u2005s (FEV\n                      <jats:sub>1<\/jats:sub>\n                      ) due to fibrotic scarring of the small airways, accounts for most CLAD cases. Pirfenidone, an antifibrotic agent used for idiopathic pulmonary fibrosis, was assessed for treating progressive BOS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      An investigator-initiated, international, multicentre, randomised, double-blind, placebo-controlled phase II trial was conducted in nine European lung transplant centres. Adults with bilateral lung transplants and progressive BOS were randomised (1:1) to receive pirfenidone 2403\u2005mg\u00b7day\n                      <jats:sup>\u22121<\/jats:sup>\n                      or placebo with standard care for 26\u2005weeks. The primary end-point was change in FEV\n                      <jats:sub>1<\/jats:sub>\n                      from baseline to week 26, with imputation for missing values.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>\n                      From 1 May 2015 to 1 December 2019, 477 patients were screened, and 90 were randomised to pirfenidone (n=48) or placebo (n=42). Both groups showed continued decline in FEV\n                      <jats:sub>1<\/jats:sub>\n                      from baseline to week 26, with no significant difference in intention to treat (ITT), ITT with imputation, or per-protocol analyses. Secondary end-points (graft loss, death, re-transplantation) were similar between groups. Treatment-related serious adverse events were distributed equally.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation<\/jats:title>\n                    <jats:p>Pirfenidone did not show superiority over placebo and standard care in this exploratory trial. It cannot be recommended for treating BOS. Further research is needed to explore other treatments for CLAD to improve long-term outcomes after lung transplantation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/13993003.02154-2024","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T16:10:15Z","timestamp":1763050215000},"page":"2402154","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["A European multicentre, randomised controlled trial of pirfenidone in bronchiolitis obliterans syndrome after bilateral lung transplantation"],"prefix":"10.1183","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9740-1246","authenticated-orcid":false,"given":"Michael","family":"Perch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Corris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Lordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Bessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5630-0155","authenticated-orcid":false,"given":"Jesper","family":"Magnusson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3048-2429","authenticated-orcid":false,"given":"Geert M.","family":"Verleden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3468-9251","authenticated-orcid":false,"given":"Robin","family":"Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaus","family":"Kneidinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga","family":"Leuckfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Verschuuren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9540-9022","authenticated-orcid":false,"given":"Jens","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"2026040201301458000_67.4.2402154.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2019.03.009"},{"key":"2026040201301458000_67.4.2402154.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2021.07.021"},{"key":"2026040201301458000_67.4.2402154.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2007.04.004"},{"key":"2026040201301458000_67.4.2402154.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2013.10.022"},{"key":"2026040201301458000_67.4.2402154.5","doi-asserted-by":"crossref","first-page":"6645","DOI":"10.21037\/jtd-2021-19","article-title":"Management of chronic rejection after lung transplantation","volume":"13","author":"Bedair","year":"2021","journal-title":"J Thorac Dis"},{"key":"2026040201301458000_67.4.2402154.6","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2014-205998"},{"key":"2026040201301458000_67.4.2402154.7","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00068310"},{"key":"2026040201301458000_67.4.2402154.8","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3390\/jcm11010111","article-title":"Beyond bronchiolitis obliterans: in-depth histopathologic characterization of bronchiolitis obliterans syndrome after lung transplantation","volume":"11","author":"Vanstapel","year":"2021","journal-title":"J Clin Med"},{"key":"2026040201301458000_67.4.2402154.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2021.05.014"},{"key":"2026040201301458000_67.4.2402154.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2005.00876.x"},{"key":"2026040201301458000_67.4.2402154.11","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181ae3392"},{"key":"2026040201301458000_67.4.2402154.12","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000113162.48048.AA"},{"key":"2026040201301458000_67.4.2402154.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2004.11.002"},{"key":"2026040201301458000_67.4.2402154.14","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/TP.0b013e3182584879","article-title":"Inhibitory effects of pirfenidone on dendritic cells and lung allograft rejection","volume":"94","author":"Bizargity","year":"2012","journal-title":"Transplantation"},{"key":"2026040201301458000_67.4.2402154.15","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.healun.2013.02.004","article-title":"Pirfenidone: a potential therapy for progressive lung allograft dysfunction?","volume":"32","author":"Ihle","year":"2013","journal-title":"J Heart Lung Transplant"},{"key":"2026040201301458000_67.4.2402154.16","first-page":"OA1990","article-title":"Pirfenidone in chronic lung allograft dysfunction after lung transplantation: a single-centre experience","volume":"50","author":"Bennett","year":"2017","journal-title":"Eur Respir J"},{"key":"2026040201301458000_67.4.2402154.17","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/s41409-022-01716-4","article-title":"The safety and tolerability of pirfenidone for bronchiolitis obliterans syndrome after hematopoietic cell transplant (STOP-BOS) trial","volume":"57","author":"Matthaiou","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"2026040201301458000_67.4.2402154.18","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01499-2021"},{"key":"2026040201301458000_67.4.2402154.19","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.healun.2020.07.006","article-title":"International Society for Heart and Lung Transplantation consensus statement for the standardization of bronchoalveolar lavage in lung transplantation","volume":"39","author":"Martinu","year":"2020","journal-title":"J Heart Lung Transplant"},{"key":"2026040201301458000_67.4.2402154.20","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00107514"},{"key":"2026040201301458000_67.4.2402154.21","doi-asserted-by":"crossref","first-page":"S223","DOI":"10.1016\/j.healun.2016.01.633","article-title":"FVC and FEV1 decline in chronic lung allograft dysfunction (CLAD) Phenotypes","volume":"35","author":"Todd","year":"2016","journal-title":"J Heart Lung Transplant"},{"key":"2026040201301458000_67.4.2402154.22","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/ajt.12155","article-title":"Phenotyping established chronic lung allograft dysfunction predicts extracorporeal photopheresis response in lung transplant patients","volume":"13","author":"Greer","year":"2013","journal-title":"Am J Transplant"},{"key":"2026040201301458000_67.4.2402154.23","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201002-0211OC"},{"key":"2026040201301458000_67.4.2402154.24","doi-asserted-by":"crossref","first-page":"e0193564","DOI":"10.1371\/journal.pone.0193564","article-title":"Montelukast for bronchiolitis obliterans syndrome after lung transplantation: a randomized controlled trial","volume":"13","author":"Ruttens","year":"2018","journal-title":"PLoS One"},{"key":"2026040201301458000_67.4.2402154.25","doi-asserted-by":"crossref","first-page":"S286","DOI":"10.1016\/j.healun.2022.01.703","article-title":"Survival after lung transplantation in Europe \u2013 CLAD as major cause of death","volume":"41","author":"Hofstetter","year":"2022","journal-title":"J Heart Lung Transplant"},{"key":"2026040201301458000_67.4.2402154.26","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.healun.2018.10.006","article-title":"Prognostic significance of early pulmonary function changes after the onset of chronic lung allograft dysfunction","volume":"38","author":"Todd","year":"2019","journal-title":"J Heart Lung Transplant"},{"key":"2026040201301458000_67.4.2402154.27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60405-4"},{"key":"2026040201301458000_67.4.2402154.28","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0057-2017"},{"key":"2026040201301458000_67.4.2402154.29","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.202108-980OC"},{"key":"2026040201301458000_67.4.2402154.30","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201310-1894OC"},{"key":"2026040201301458000_67.4.2402154.31","doi-asserted-by":"publisher","DOI":"10.1378\/chest.112.5.1175"},{"key":"2026040201301458000_67.4.2402154.32","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.healun.2024.05.013","article-title":"Results from randomized trial of pirfenidone in patients with chronic rejection (STOP-CLAD study)","volume":"43","author":"Combs","year":"2024","journal-title":"J Heart Lung Transplant"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.02154-2024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T08:30:32Z","timestamp":1775118632000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.02154-2024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":32,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,2]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1183\/13993003.02154-2024"],"URL":"https:\/\/doi.org\/10.1183\/13993003.02154-2024","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]}}}